Date post: | 02-Jun-2018 |
Category: |
Documents |
Upload: | satria-wardana |
View: | 228 times |
Download: | 0 times |
of 34
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
1/34
L O G O
Add your company slogan
CHAPTER 56 Unstable Angina andNon ST Elevation
Myocardial InfarctionPembimbing:dr. Nugroho Hadi S, Sp. PD, Sp. JP (K) FIHA
BRAUNWALD TEXTBOOK READING
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
2/34
DEFINITION
UA/NSTEMI non ST elevation acute coronary syndrome(NSTE-ACS). [1,2]
from severe obstruction, but not total occlusion Stable angina pectoris typically manifests as a deep, poorly
localized chest or arm discomfort (rarely described as pain), afterphysical exertion or emotional stress, and relieved on 5 -10minutes by rest or SL nitroglycerin
unstable angina : angina pectoris (or equivalent type of ischemicdiscomfort) with at least one of three features:
(1) occurring at rest (or minimal exertion) and usually >20 minutes(2) being severe and usually described as frank pain; or(3) occurring with a crescendo pattern 2/3 unstable angina elevated cardiac serum markers: NSTEMI
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
3/34
Pathophysiology
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
4/34
Thrombosis
Six sets of observations support thrombosis in thepathogenesis :
(1) thrombi in the coronary arteries,(2) the demonstration in coronary atherectomy(3) thrombus at coronary angioscopy;(4) angiography, intravascular ultrasound, optical
coherence tomography, and CT angiography ofplaque ulceration or irregularities suggesting a
ruptured plaque or thrombus;(5) the elevation of several serum markers of plateletactivity and fibrin formation; and
(6) the improvement in clinical outcome byantiplatelet and antithrombotic therapy.
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
5/34
Platelet Activation and Aggregation
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
6/34
Clinical Presentation
Clinical Examination ischemia involves a large fraction LV
Electrocardiography ST depression (or transient ST elevation) and T
wave changes occur in up to 50% New (orpresumably new) ST- segment deviation (0.1mV). [9]
T wave changes are sensitive but not specific foracute ischemia unless they are marked (>0.3 mV)(Fig. 56-4).
Continuous ecg monitoring purposes: (1)identify arrhythmias and (2) identify recurrent ST-segment deviation indicative of ischemia
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
7/34
Markers of Cardiac Necrosis
symptoms consistent with UA/NSTEMI+elevations of markers of myocardial necrosis NSTEMI.
Troponins more sensitive than CK-MB andassociated with a worse prognosis. [11]
false-positive troponin elevations but noepicardial stenoses at coronary angiography.[13]
Patients presenting with UA/NSTEMI whohad elevations of troponin but no apparentCAD on angiography had a significantlyworse prognosis than those who weretroponin negative without coronary disease
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
8/34
chest radiograph : pulmonary congestion or edema total cholesterol and HDL levels fall 30-40% 24 hours after
UA/NSTEMI or STEMI measured at initial presentation.
Noninvasive Testing purposes:
(1) diagnose the presence or absence of CAD(2) evaluate residual ischemia after medical therapy;(3) evaluate left ventricular function;
(4) in risk stratification
Stress myocardial perfusion imaging or stressechocardiography is slightly more sensitive than ecg stresstesting and has greater prognostic value
Exercise testing is generally recommended unless the patientcannot walk sufficiently pharmacologic stress testing
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
9/34
Clinical Classification
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
10/34
Risk Stratification
High-Risk Clinical Subgroups
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
11/34
Risk Assessment by Electrocardiography independentpredictors of 1-year death or MI included LBBB, ST-segment deviation >0.05 Mv, and both P < 0.001. [9]
Risk Assessment by Cardiac Markers
Markers ofmyocyte necrosis(CKMB/troponin)
CRP White blood cellcount
myeloperoxidaseNatriuretic
peptide Creatinin
Glucose Thrombusprecursor protein
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
12/34
Combined Risk Assessment Scores
The TIMI risk score:
age >65 years, >3 risk factors for
CAD, documented CAD at
catheterization ST deviation >0.5
mm, >2 episodes of
angina in last 24hours, ASA within prior
week, elevated cardiac
markers.
The Global Registryof Acute Coronary
Events (GRACE) increased mortality;
age
Killip
HR ST-segment
depression
signs of heart failure
lower SBP
cardiac arrest
creatinine /cardiacmarker. [44]
A risk score to predictmajor bleeding
CRUSADE registry
creatinineclearance,
women diabetics lower BP Higher HR
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
13/34
Medical TherapyRelief of chest pain is an initial goal of treatment.
morphine sulfate by intravenous
NitratesContraindications: hypotension and the use of sildenafil or relatedphosphodiesterase type 5 inhibitors within 24 to 48 hours
Beta Blockersreducing subsequent MI or recurrent ischemia, reduce reinfarctionand ventricular fibrillation
initiated within the first 24 hours for patients with no: (1) signs ofheart failure, (2) low-output state, (3) increased risk for cardiogenicshock, or (4) relative CI(PR interval >0.24 second, 2-3-degree heartblock, active asthma, or reactive airway disease).
CCB
persistent ischemia despite nitrates and beta blockers,contraindications to beta blockers, and hypertension.
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
14/34
Anti thrombotic therapy
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
15/34
Aspirin (ASA)
Acetylates platelet cyclooxygenase 1(COX-1) blocking the synthesis andrelease of thromboxane A 2 decreasesplatelet aggregation and arterial thrombusformation.Irreversible
Contraindications: allergy, active bleeding,and a known platelet disorder
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
16/34
ADP AntagonistsThienopyridinesprodrugs that are converted to active metabolites through oxidationby the hepatic cytochrome P-450 system [61] inhibit platelet aggregation by inhibiting irreversibly the binding ofadenosine diphosphate (ADP) to platelet P2Y 12 receptors andincrease bleeding time
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
17/34
Clopidogrel
Initiation 75 mg daily platelet inhibition after 3 -5 days300 mg effective platelet inhibition within 4 -6 hours. [69] 600-mg loading dose achieves a steady-state level ofplatelet inhibition after just 2 hours
Nonresponders or hyporesponders to clopidogrel havebeen identified in several studies. [72-74]
Hyporesponsiveness more common among DM, obesity,
advanced age, and a genetic polymorphism of thecytochrome P-450 system 150 mg/daily; prasugrel 10mg/day, or potentially by adding cilostazol
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
18/34
Prasugrel generation of the prasugrelmetabolite is approximately 10 times asgreat as with clopidogrel administration,resulting in a roughly 10 times greaterpotency.
Ticagrelor whose active metabolites areirreversible platelet inhibitors, ticagrelor* isa reversible blocker of the P2Y 12 plateletreceptor that acts directly on the platelet
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
19/34
Glycoprotein IIb/IIIa Inhibitors
These drugs block the final common pathway of plateletaggregation, the fibrinogen-mediated cross-linkage of interfere with platelet aggregation caused by all types of stimuli(e.g., thrombin, ADP, collagen, serotonin).
abciximab, a monoclonal antibody, approved only in patientsundergoing PCI, and eptifibatide and tirofiban (small moleculeinhibitors).
Opinion is divided on the optimal timing of the administration of GP
IIb/IIIa inhibitors. Some advocate starting these drugs at the time ofpresentation, whereas others reserve it for use during PCI. The ACC/AHA Guidelines have indicated that either strategy isacceptable. [2]
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
20/34
Anticoagulants
HeparinVariability effects from the heterogeneity of UFH andthe neutralization of heparin by circulating plasma factorsand by proteins released by activated platelets. [99] Monitoring : activated partial thromboplastin time (APTT)is 50 to 70 seconds or 1.5 to 2.5 times control (every 6hours until the target range is reached and every 12 to24 hours thereafter)
Adverse effects include bleeding, especially when APTTis elevated, and heparin-induced thrombocytopenia,which is more common with longer durations oftreatment
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
21/34
Low-Molecular-Weight Heparininhibition of factors IIa and Xaadvantages over UFH:(1) greater anti factor Xa activity inhibits thrombin generation moreeffectively;
(2) induces a greater release of tissue factor pathway inhibitor , andit is not neutralized by platelet factor 4 [101] ;(3) LMWH causes thrombocytopenia at a lower rate [100] ;(4) the high bioavailability allows subcutaneous administration; and(5) LMWH binds less avidly than UFH to plasma proteins and
therefore has a more consistent anticoagulant effect.
Monitoring of the level of anticoagulation is not necessary.
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
22/34
potential advantage over indirect thrombin inhibitors, (UFH, LMWH) do not require antithrombin and can inhibit clot-bound thrombin,do not interact with plasma proteins, provide a stable level ofanticoagulation, and do not cause thrombocytopenia
Direct ThrombinInhibitors
Among patients without a coronary stent but with another indicationfor warfarin, such as chronic atrial fibrillation or severe left
ventricular dysfunction, who are at high risk of systemicembolization, the combination of ASA and warfarin would bepreferable as the long-term antithrombotic strategy.
Oral Anticoagulation
rivaroxaban, apixabanFactor Xa
Inhibitors:
Thrombin potently stimulates platelets by activating PAR-1. Thethrombin receptor blocker Vorapaxar blocks this interaction
Protease-ActivatedReceptor (PAR-1)
Antagonists
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
23/34
Prinzmetal Variant Angina
syndrome of ischemic pain that occurred at rest, accompanied byST-segment elevation.
MechanismsThe original hypothesis: transient increases in coronary
vasomotor tone or vasospasm.reduction in nitric oxide productionEnhanced phospholipase C (PLC) activity.inflammatoryPolymorphisms of the alpha 2 presynaptic and the postsynapticbeta 2 receptor may also associate with PVA. [155]
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
24/34
youngermany are often heavy cigarette smokers.The anginal pain is often extremely severe withsyncope related to atrioventricular block,asystole, or ventricular tachyarrhythmias.
ECG: episodic ST-segment elevation often withsevere chest pain, usually occurring at rest ;
multiple episodes of asymptomatic (silent) ST-segment elevation.Provocative Tests: Ergonovine; Acetylcholine
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
25/34
Management
urged strongly to discontinue smokingThe mainstay of therapy is a calcium antagonistalone or in combination with a long-acting nitrateResponse to beta blockade in patients with PVAis variable.
Prazosin, a selective alpha-adrenergic receptorblocker, may also have value
ASA, increase the severity of ischemic episodesPVA because it inhibits biosynthesis coronaryvasodilator prostacyclin.CCB should be continued for at least 6 monthsafter successful revascularization in patients
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
26/34
Guidelines UA/NSTEMI
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
27/34
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
28/34
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
29/34
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
30/34
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
31/34
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
32/34
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
33/34
8/10/2019 CHAPTER 56 Unstable Angina and NonST Elevation
34/34